Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces the completion of a Series B funding round of €21.3M. The proceeds will enable the company to expand the list of indications for its lead compound, MIN-102, as well as to conduct a new clinical trial for a second orphan central nervous system (CNS) indication. The funding round was led by Fund+, joined by SFPI-FPIM, S.R.I.W. and Sambrinvest, in addition to all Series A investors. “Minoryx Therapeutics is a very promising company, at the leading edge of innovation in the field of rare diseases of genetic origin with a high unmet medical need”, said Philippe Monteyne, Fund+. “We are very pleased to reinforce the link between Spain and Belgium, in particular with the Walloon ecosystem of the Charleroi Brussels South Biopark.”
said Gery Lefebvre, SRIW. Discover the official press release here.
Bone Therapeutics announces positive final results in the Phase I/IIA delayed-union study of its allogeneic bone cell therapy product ALLOB in 21 patients, supporting the future clinical development of the delayed union indication. The Company also announces the development of an optimized production process for ALLOB, which the Company believes delivers critical improvements in consistency, scalability, cost-effectiveness and ease of use. Discover the official press release here.Read more